Related Experiment Video

Updated: Jun 10, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

Treatment of multidrug resistant advanced alveolar soft part sarcoma with sunitinib

Abhimanyu Ghose1, Zeeshan Tariq, Salvatore Veltri

  • 1Department of Medicine, University of Toledo, Toledo, OH 43614, USA. abhimanyu.ghose@utoledo.edu

American Journal of Therapeutics
|July 17, 2010
PubMed

Insights

Sunitinib shows promise for treating alveolar soft part sarcoma, a rare cancer. This tyrosine kinase inhibitor led to tumor regression and improved quality of life in a patient resistant to chemotherapy.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Sunitinib is an established tyrosine kinase and angiogenesis inhibitor.
  • It has demonstrated efficacy in treating gastrointestinal stromal tumors and advanced renal cell carcinoma.

Observation:

  • A case report details a patient with aggressive alveolar soft part sarcoma (ASPS).
  • The patient had lung and bone metastases and had not responded to multiple chemotherapy regimens.

Findings:

  • Sunitinib treatment resulted in complete regression of the primary tumor.
  • Stabilization of bone metastases and significant improvement in quality of life were observed.
  • The patient showed a significant response to sunitinib therapy.

Implications:

  • Sunitinib may play a key role in managing non-gastrointestinal stromal tumors, such as alveolar soft part sarcoma.
  • Further clinical trials are warranted to explore sunitinib's potential in treating ASPS.
  • This case highlights sunitinib as a promising therapeutic option for rare cancers.

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies

Published on: July 28, 2020

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...